Aeglea Bio Therapeutics Top Management
Aeglea Bio employs about 69 people. The company is managed by 11 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 6.27 employees per reported executive. Evaluation of Aeglea Bio's management performance can provide insight into the firm performance.
| Scott Rowlinson President Vice President - Research |
Aeglea |
Aeglea Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.4182) % which means that it has lost $0.4182 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8141) %, meaning that it created substantial loss on money invested by shareholders. Aeglea Bio's management efficiency ratios could be used to measure how well Aeglea Bio manages its routine affairs as well as how well it operates its assets and liabilities.Aeglea Bio Workforce Comparison
Aeglea Bio Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 992. Aeglea Bio holds roughly 69.0 in number of employees claiming about 7% of equities under Health Care industry.
Aeglea Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aeglea Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aeglea Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aeglea Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stelzer Laurie over a year ago Acquisition by Stelzer Laurie of 50000 shares of Aeglea Bio subject to Rule 16b-3 | ||
Smith Hunter C over a year ago Acquisition by Smith Hunter C of 1950000 shares of Aeglea Bio subject to Rule 16b-3 |
Aeglea Bio Notable Stakeholders
An Aeglea Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aeglea Bio often face trade-offs trying to please all of them. Aeglea Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aeglea Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Scott Rowlinson | Vice President - Research | Profile | |
| Joey Perrone | Director- Finance, IR Contact Officer | Profile | |
| James JD | Pres CEO | Profile | |
| Jonathan MBA | CFO Officer | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Josie Gayton | Operations Strategy | Profile | |
| Cortney MBA | VP Operations | Profile | |
| Leslie Sloan | Chief Officer | Profile | |
| Kelly Boothe | Sr Relations | Profile | |
| Jeffrey Goldberg | CEO Pres | Profile | |
| MBA MD | Chief Officer | Profile |
Aeglea Bio Workforce Analysis
Traditionally, organizations such as Aeglea Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aeglea Bio within its industry.Aeglea Bio Manpower Efficiency
Return on Aeglea Bio Manpower
| Revenue Per Employee | 33.8K | |
| Revenue Per Executive | 211.7K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 7.6M | |
| Working Capital Per Employee | 689.9K | |
| Working Capital Per Executive | 4.3M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |